INOVIQ is collaborating with The University of Queensland to develop INOVIQ’s EXO-OC screening test for the early detection of ovarian cancer. Previous studies have shown overall accuracy of 94% for detection of ovarian cancer across all stages and achieved a sensitivity of more than 90% and specificity of 96% for stage I, where women have a 5-year survival rate of over 90%. INOVIQ is planning clinical studies to support an initial US launch of the test for screening OC in asymptomatic high-risk women.

INOVIQ is collaborating with The University of Queensland to develop INOVIQ’s EXO-OC screening test for the early detection of ovarian cancer. Previous studies have shown overall accuracy of 94% for detection of ovarian cancer across all stages and achieved a sensitivity of more than 90% and specificity of 96% for stage I, where women have a 5-year survival rate of over 90%. INOVIQ is planning clinical studies to support an initial US launch of the test for screening OC in asymptomatic high-risk women.

INOVIQ is featured on page 18